Market access routes for genomic diagnostics (GDx) in England are causing delays and inefficiencies for manufacturers, patients, and the National Health Service (NHS) itself, according to an independent whitepaper commissioned by the British In Vitro Diagnostics Association (BIVDA).
Key Takeaways
-
British market access pathways are unclear and complex for GDx
-
There are regional inequalities in access to innovative tests due to local commissioning
...
England’s labyrinthine funding and reimbursement pathways lead to delays in access to tests that, in some therapeutic areas such as cancer, can guide clinicians on the appropriate and effective drug...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?